Bilan français des effets indésirables du vaccin Prévenar 13(®)

OBJECTIVE: To describe the profile and the incidence of adverse events (AEs) reported with Prevenar 13(®) since its commercialization. METHOD: Analysis of all adverse events reported with Prevenar 13(®) in France between 1st July 2010 and 31 October 2014. RESULTS: In 4 years and 4 months, 376 AEs, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Agier, M.-S., Marchand, S., Paret, N., Gautier, S., Jonville-Béra, A.-P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133411/
https://www.ncbi.nlm.nih.gov/pubmed/28242152
http://dx.doi.org/10.1016/j.arcped.2017.01.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133411/
https://www.ncbi.nlm.nih.gov/pubmed/28242152
http://dx.doi.org/10.1016/j.arcped.2017.01.018

Ejemplares similares